Hi-511 Inhibits Both BRAF and AURKB To Overcome Malignant Melanoma Drug Resistance and Metastasis
2020-05
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
Hi-511 Inhibits Both BRAF and AURKB To Overcome Malignant Melanoma Drug Resistance and Metastasis
Authors
Published Date
2020-05
Publisher
Type
Thesis or Dissertation
Abstract
Melanoma is an aggressive tumor of the skin. Although BRAF V600E inhibitors have been developed to treat melanoma, drug resistance and metastasis are still the major problems in melanoma therapy. Novel targets and effective agents to overcome drug resistant melanoma and reduce metastasis are urgently needed in clinical therapy. In this study, AURKB was defined as the target for melanoma therapy in an effort to overcome drug resistance. Notably, HI-511, a novel dual-target inhibitor for AURKB and BRAF V600E, inhibits development of both drug-sensitive and drug-resistant melanoma. We analyzed the Gene Expression Omnibus (GEO) database, utilized gene editing, and a xenograft mouse model to show AURKB is crucial for development of both drug-sensitive and drug-resistant melanoma. Inhibition of AURKB suppresses the cell growth and the rate of induced apoptosis in melanoma. Knocking down expression of AURKB decreased activation of the BRAF/MEK/ERKs and PI3K/AKT signaling pathways. Notably, a novel AURKB and BRAF V600E dual-target inhibitor HI-511 was developed. HI-511 strongly suppresses development of vemurafenib-sensitive and vemurafenib-resistant melanoma in vitro and in vivo, which is evidenced by in vitro kinase assays, cell base studies, xenograft mouse models and the BRAF V600E/PTEN-loss melanoma mouse model. Moreover, we also analysis the metastatic melanoma database and utilized the wound healing assay and a luciferase-linked xenograft mouse model to demonstrate HI-511 could reduce melanoma metastasis. Overall, AURKB could be a potential target for melanoma treatment and could overcome the resistance to BRAF V600E inhibitor and reduce melanoma metastasis. HI-511 is a novel dual-target inhibitor for both AURKB and BRAF V600E and could achieve durable suppression of melanoma, even drug-resistant melanoma and metastatic melanoma.
Description
University of Minnesota Ph.D. dissertation. May 2020. Major: Biomedical Informatics and Computational Biology. Advisor: Zigang Dong. 1 computer file (PDF); x, 178 pages.
Related to
Replaces
License
Collections
Series/Report Number
Funding information
Isbn identifier
Doi identifier
Previously Published Citation
Suggested citation
Chang, Xiaoyu. (2020). Hi-511 Inhibits Both BRAF and AURKB To Overcome Malignant Melanoma Drug Resistance and Metastasis. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/216163.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.